EUVIMEDEUVIMED entdecken
Crossref

An Automated Assay for Carbapenemase Detection in Enterobacterales: a Real-World Performance

Yu Kyung Kim, Young Deok Park, Jung Ok Kim, Soon Hee Chang, Kyung Eun Song

Clinical Laboratory · 2025

DOI: 10.7754/clin.lab.2025.250150 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Laboratory, 2025. Verfasst von Yu Kyung Kim und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: beta-Lactamases, Bacterial Proteins, Enterobacteriaceae, Enterobacteriaceae Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Carbapenem-resistant Gram-negative organisms pose a significant challenge to global healthcare, making the reliable detection and classification of carbapenemases essential for informed therapy and infection control. The BD Phoenix CPO detect assay offers simultaneous carbapenemase detection and Ambler classification in routine antimicrobial susceptibility testing. Accordingly, this study analyzed real-world data on the BD Phoenix CPO test to evaluate its performance in clinical settings over a period of two years. METHODS: We analyzed 298 samples using BD Phoenix CPO detect assay, Xpert Carba-R polymerase chain reaction (PCR), and conventional PCR from January 2021 through December 2022 to identify and confirm carbapenemase genes. The BD Phoenix system was used for antimicrobial susceptibility testing and carbapenemase classification. The Xpert Carba-R kit detected five key carbapenemase genes (blaKPC, blaNDM, blaVIM, blaIMP, and blaOXA-48), while conventional PCR identified these five genes and additional five carbapenemase genes (blaGES, blaSPM, blaSME, blaSIM, and blaGIM). The PCR results were compared with those from the Phoenix system. RESULTS: Sputum was the most common specimen type, and Klebsiella pneumoniae accounted for 86.9% of the identified species. The concordance between the BD Phoenix assay and PCR for identifying carbapenemase genes showed 98.8%, 35.3%, and 71.4% agreement for Ambler class A, B, and D, respectively. The Phoenix had a false positive rate of 9.0%. Additionally, 21.2% of carbapenemase-positive cases had uncertain classifications. The con-cordance between Carba-R PCR and conventional PCR was 98.4%, with positive and negative agreement of 98.2% and 86.2%, respectively. CONCLUSIONS: The BD Phoenix CPO test provides a significant advantage of delivering results concurrently with antimicrobial susceptibility testing, representing a highly valuable tool for routine screening in clinical practice. Nevertheless, its high false positive rate underscores the necessity of confirmatory testing to ensure accurate carbapenemase classification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-LactamasesBacterial ProteinsEnterobacteriaceaeEnterobacteriaceae InfectionsCarbapenem-Resistant EnterobacteriaceaeHumansMicrobial Sensitivity TestsPolymerase Chain ReactionAnti-Bacterial Agents

Substanzen

beta-LactamasescarbapenemaseBacterial ProteinsAnti-Bacterial Agents

Zitieren

APA

Kim, Y. K., Park, Y. D., Kim, J. O., Chang, S. H., & Song, K. E. (2025). An Automated Assay for Carbapenemase Detection in Enterobacterales: a Real-World Performance. Clinical Laboratory. https://doi.org/10.7754/clin.lab.2025.250150

Vancouver

Kim YK, Park YD, Kim JO, Chang SH, Song KE. An Automated Assay for Carbapenemase Detection in Enterobacterales: a Real-World Performance. Clinical Laboratory. 2025. doi:10.7754/clin.lab.2025.250150

BibTeX
@article{Kim2025,
  author = {Kim, Yu Kyung and Park, Young Deok and Kim, Jung Ok and Chang, Soon Hee and Song, Kyung Eun},
  title = {An Automated Assay for Carbapenemase Detection in Enterobacterales: a Real-World Performance},
  journal = {Clinical Laboratory},
  year = {2025},
  doi = {10.7754/clin.lab.2025.250150}
}
Kostenlos starten →